2008 - Review: Limited evidence suggests that statins are safe in patients with liver disease

Bates, Eric R.
August 2008
ACP Journal Club;8/19/2008, Vol. 149 Issue 2, p10
Academic Journal
The article focuses on a study regarding the use of statins in patients with liver disease and presents the author's views on it. It describes the procedure of the study, which revealed that statins are safe in patients with preexisting liver disease. The author argues that monitoring serum transaminase levels in the general population taking statins is not useful or cost-effective and that it might deprive many patients of the benefits of statin therapy.


Related Articles

  • COMMENTARY. Bates, Eric R. // Evidence Based Medicine;Oct2008, Vol. 13 Issue 5, p140 

    The article focuses on the statin therapy in patients with pre-existing liver disease. In notes that statins occasionally cause asymptomatic serum transaminase elevations. However, these elevations are resolved in 70% of cases with continued therapy or when therapy is discontinued without...

  • Expanding statin use "would be cost-effective" in US.  // PharmacoEconomics & Outcomes News;7/23/2011, Issue 633, p7 

    The article focuses on a study which examined the cost effectiveness of expanded statin prescribing strategies among people with coronary heart disease in the U.S.

  • When is it cost effective to treat diabetes patients with statins?  // PharmacoEconomics & Outcomes News;Apr2014, Vol. 700 Issue 1, p10 

    The article discusses research being done on the cost-effectiveness of statins for primary prevention in patients with type 2 diabetes, which references a study by F. M. de Vries et al. published in the March 2014 issue of "Value in Health."

  • Discontinuation of Statin Treatment in Relation to Chronic Diseases and Laboratory Findings. Niskanen, Leo; Suvisaari, Janne; Suvisaari, Jaana; But, Anna; Haukka, Jari // Pharmacology & Pharmacy;Jun2013, Vol. 4 Issue 3, p318 

    Purpose: The aim was to study discontinuation of statin treatment, especially with respect to clinical characteristics and adverse effect measured by clinical laboratory tests indicating muscle damage (plasma creatine kinase, CK) and liver AEs (plasma alanine aminotransferase, ALAT). Methods:...

  • The Myth of Statin-Induced Hepatotoxicity. Bader, Ted // American Journal of Gastroenterology;May2010, Vol. 105 Issue 5, p978 

    The article examines the involvement of isolated alanine aminotransferase (ALT) elevations associated with statin therapy in drug-induced liver injury. A placebo-controlled trial that was conducted shows that atorvastatin has no participation in hepatotoxicity. However, another two trials...

  • Dutch statin switch making sound economic sense?  // PharmacoEconomics & Outcomes News;10/2/2010, Issue 613, p7 

    The article discusses research on the switch to simvastatin from atorvastatin in the Netherlands, which references the study "The Health and Economics Impact of Switching From Atorvastatin to Generic Simvastatin in the Netherlands," by D. Liew et al.

  • Call to boost statin theraphy adherence.  // Independent Nurse;1/18/2010, p10 

    The article reports on the results of several studies conducted in Great Britain which showed that enhancing adherence to statin therapy could have broader effect than spreading its use.

  • Continued statin therapy could improve the outcome after spontaneous intracerebral hemorrhage. Tapia-Pérez, J.; Rupa, R.; Zilke, R.; Gehring, S.; Voellger, B.; Schneider, T. // Neurosurgical Review;Apr2013, Vol. 36 Issue 2, p279 

    Spontaneous intracerebral hemorrhage (ICH) often represents a devastating event despite maximal therapeutic efforts. Statins are drugs primarily used as cholesterol reducers with several pleiotropic effects that may result in neuroprotection. In this study, we assessed the continued use of...

  • Broader sharing of liver allografts cost effective.  // PharmacoEconomics & Outcomes News;5/28/2011, Issue 629, p4 

    The article focuses on a study which examined the cost effectiveness of broader sharing of liver allografts in patients diagnosed with end-stage liver disease.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics